SRC inhibition represents a potential therapeutic strategy in liposarcoma

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Liposarcomas (LS) are the most common malignant mesenchymal tumors, associated with a high mortality rate.
• LS present with diverse subtypes, including well-differentiated/dedifferentiated (WDLS/DDLS), myxoid/round cell (MLS), and pleomorphic (PLS).
• Identifying novel therapeutic targets is critical for improving patient outcomes in liposarcoma.

Purpose of the Study:

• To investigate the functional role of SRC kinase in primary human liposarcomas and derived cell lines.
• To evaluate SRC as a potential therapeutic target for liposarcoma treatment.

Main Methods:

• Immunohistochemistry and Western blot analysis to assess SRC activation levels.
• siRNA-mediated SRC knockdown and SRC inhibitor Dasatinib treatment in LS cell lines.
• MTT assays, flow cytometry, and cell migration/invasion assays to evaluate cellular responses.

Main Results:

• Activated SRC (p-Tyr416-SRC) was detected in various LS subtypes, with notable activation in MLS and PLS.
• SRC inhibition via Dasatinib or siRNA significantly reduced LS cell proliferation, induced apoptosis, and decreased mitotic activity.
• Dasatinib treatment led to dephosphorylation of SRC, FAK, IGF-IR, and AKT, and reduced migratory and invasive potential in MLS cells.

Conclusions:

• SRC kinase activation is implicated in liposarcoma biology, influencing proliferation, apoptosis, and cell motility.
• SRC represents a promising therapeutic target for liposarcomas, particularly for the MLS and PLS subtypes.